Grace Anne Longfellow

Grace Anne Longfellow

Auto-generated profile, based on publicly available information

Grace Anne Longfellow


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2025 in JMIR Cancer
Verified
Journal Article
Open access
AJAnna Rose Johnson
Anna Rose Johnson
GLGrace Anne Longfellow
Grace Anne Longfellow
CLClara N Lee
Clara N Lee
BOBenjamin Ormseth
Benjamin Ormseth
GSGary Skolnick
Gary Skolnick
TMTerence M. Myckatyn
Terence M. Myckatyn
Background: Decision aids improve patient and clinician decision-making but are underused and often restricted to clinical settings. Objective: Given limited studies analyzing the feasibility of disseminating decision aids through social media, this study aimed to evaluate the acceptability, trust, and engagement of women with social media as a tool to deliver online decision aids for cancer treatment. Methods: To prepare for potential dissemination of a breast cancer decision aid via social media, a cross-sectional survey in February 2023 was conducted via Prime Panels, an online market research platform, of women aged 35-75 years in the United States. Demographics, health, cancer information-seeking behaviors, social media use, trust in social media for health information, as well as the likelihood of viewing cancer-related health information and clicking on decision aids through social media, were assessed. Statistical analyses included descriptive statistics, correlations, and multivariable ordinal regression. Results: Of 607 respondents, 397 (65.4%) had searched for cancer information, with 185 (46.6%) using the internet as their primary source. Facebook (Meta) was the most popular platform (511/607, 84.2%). Trust in social media for health information was higher among Black (14/72, 19.4%) and Asian respondents (7/27, 25.9%) than among White respondents (49/480, 10.2%; P=.003). Younger respondents aged 35-39 years (17/82, 20.7%) showed higher trust than those aged 70-79 years (12/70, 17.1%; P<.001). Trust in social media for health information was linked to a higher likelihood of viewing cancer information and accessing a decision aid online (P<.001). Participants who rated social media as “Trustworthy” (n=73) were more likely to view cancer information (61/73, 83.6%) and click on decision aids (61/73, 83.6%) than those who found it “Untrustworthy” (n=277; view: 133/277, 48.0%; click: 125/277, 45.1%). Engagement with social media positively correlated with viewing online cancer information (Spearman ρ=0.20, P<.001) and willingness to use decision aids (ρ=0.21, P<.001). Multivariable ordinal regression analyses confirmed that perception of social media’s trustworthiness is a significant predictor of engagement with decision aids (untrustworthy vs trustworthy β=–1.826, P<.001; neutral vs trustworthy β=–0.926, P=.007) and of viewing cancer information (untrustworthy vs trustworthy β=–1.680, P<.001, neutral vs trustworthy β=–0.581, P=.098), while age and employment status were not significant predictors. Conclusions: This exploratory study suggests that social media platforms may increase access to health information and decision aids. No significant differences were observed between demographic variables and the use or trust in social media for health information. However, trust in social media emerged as a mediating factor between demographics and engagement with cancer information online. Before disseminating decision aids on social media, groups should identify existing trust and engagement patterns with different platforms within their target demographic.

17 July 2025 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
CKCuneyt Koksoy
Cuneyt Koksoy
ITIlse Torres-Ruiz
Ilse Torres-Ruiz
SBSydney E. Browder
Sydney E. Browder
NGNikita Y. Gidh
Nikita Y. Gidh
GLGrace Anne Longfellow
Grace Anne Longfellow
JCJayer Chung
Jayer Chung

28 September 2025 in Clinical Medicine Insights: Case Reports
Verified
Journal Article
Open access
GLGrace Anne Longfellow
Grace Anne Longfellow
SHStephen M. Himmelberg
Stephen M. Himmelberg
AJAlexander D. Jeffs
Alexander D. Jeffs
RDReid W. Draeger
Reid W. Draeger
Background: Prosthetic joint infection (PJI) following proximal interphalangeal joint (PIPJ) arthroplasty is rare, with most reported cases involving bacterial organisms. Fungal PJIs comprise <1% of all PJIs, with Fusarium species an exceptionally uncommon cause, particularly in the upper extremity. Case Presentation: A 60-year-old female with a history of rheumatoid arthritis on methotrexate and adalimumab underwent right long finger PIPJ silicone arthroplasty. She presented 12 weeks postoperatively with pain, swelling, and radiographic changes concerning for PJI despite normal inflammatory markers. Implant explantation with debridement was performed, and intraoperative cultures grew Fusarium species. Initial oral voriconazole was insufficient, necessitating readmission for intravenous liposomal amphotericin B and oral posaconazole. Thirty-nine days after completing her 6-month antifungal course, she underwent arthrodesis, which later failed, requiring revision with iliac crest autograft and dorsal plate fixation. At latest follow-up, she remained pain-free with radiographic union and no recurrent infection. Conclusions: Based on available literature, this represents the first reported case of Fusarium PJI following silicone arthroplasty of the hand. This underscores the importance of maintaining suspicion for atypical pathogens in immunosuppressed hosts and highlights the complexities managing fungal infections in small joint arthroplasty.

25 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LCLauren Cook
Lauren Cook
GLGrace A. Longfellow
Grace A. Longfellow
JKJulia Kessel
Julia Kessel
BTBrian D. Thorp
Brian D. Thorp
Adam KimpleAdam Kimple
Adam Kimple
CECharles S Ebert
Charles S Ebert
Background/Objectives: Subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are commonly used for allergic rhinitis (AR), yet limited research has directly compared their effects on quality of life (QoL). We aimed to assess QoL differences between SLIT and SCIT recipients. As both forms of immunotherapy have reported benefits, we hypothesize that patients undergoing SLIT and SCIT will have comparable QoL improvements. Methods: A cohort study included patients with AR treated with immunotherapy from 2018 to 2022. Patients with obstructive sleep apnea, primary ciliary dyskinesia, cystic fibrosis, vasculitis, rheumatoid arthritis, sarcoidosis, or lupus were excluded. QoL was evaluated using the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) at multiple time points. Demographics, additional therapies, and allergen sensitivities were recorded. Data were analyzed using SPSS Statistics. Results: A total of 41 participants were eligible for inclusion. Both SLIT and SCIT groups exhibited reductions from baseline RQLQ scores. Within SLIT recipients, 5/7 RQLQ domains significantly improved. SCIT recipients showed significant QoL enhancement in 3/7 domains. The mean difference between SLIT and SCIT cohorts was −0.18 (p = 0.57, d = −0.18, 95% CI [−0.79, 0.43] at a mean treatment time of 18 months. Conclusions: SLIT and SCIT showed comparable RQLQ score reductions after 18 months of therapy, suggesting similar QoL benefits between the two treatment paradigms. Further investigation is needed to explore SLIT vs. SCIT differences in long-term QoL improvements beyond two years.

2 August 2025 in The Laryngoscope
Verified
Journal Article
Closed access
GLGrace Anne Longfellow
Grace Anne Longfellow
ECElena Quinonez Del Cid
Elena Quinonez Del Cid
LCLauren Cook
Lauren Cook
AMAurelia Monk
Aurelia Monk
ADAmelia F. Drake
Amelia F. Drake